NCCN Funding Opportunities

National Comprehensive Cancer Network® (NCCN®) is pleased to announce a collaboration with AstraZeneca Pharmaceuticals (AstraZeneca) to offer a new funding opportunity for NCCN Member Institution faculty. This opportunity is seeking Letters of Intent (LOIs), and ultimately proposals, to improve the quality of care, including the delivery of guideline-concordant care, and additional innovations in the care delivery for patients with limited and extensive stage Small Cell Lung Cancer (LS-SCLC and ES-SCLC). Please note that this document can also be accessed online at https://www.nccn.org/education-research/nccn-oncology-research-program/orp-main-page.

RFP: NCCN and AstraZeneca Quality Improvement Initiative: Improving the Quality of Care and Application of Best Practices in the Treatment of Patients with Small Cell Lung Cancer (SCLC) Research Grant Opportunity

Proposal Due By: Monday, June 27, 2022, by 5:00 pm ET

Open to: NCCN Member Institution Faculty

NCCN views this collaboration with AstraZeneca as clear recognition of the advantages offered to NCCN Member Institutions through the NCCN Oncology Research Program. We hope you and your colleagues will be interested in this opportunity.

Letter of Intent must be submitted by 5:00 pm ET on Monday, June 27, 2022. Please direct questions regarding this RFP to Nicole Zion at zion@nccn.org with the subject line, “2022 NCCN AZ SCLC RFP.”